Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
National Cancer Institute (NCI)
David M Gershenson; Austin Miller; William E Brady; James Paul; Karen Carty; William Rodgers; David Millan; Robert L Coleman; Kathleen N Moore; Susana Banerjee; Kate Connolly; Angeles Alvarez Secord; David M O'Malley; Oliver Dorigo; Stephanie Gaillard; Hani Gabra; Brian Slomovitz; Parviz Hanjani; John Farley; Michael Churchman; Ailith Ewing; Robert L Hollis; C Simon Herrington; Helen Q Huang; Lari Wenzel; Charlie Gourley
NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. ; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.